

Evaluation of Seroconversion Rate Following SARS COV 2 Vaccination in Health Care Workers at Shahid Beheshti University of Medical Sciences

Masoud Alavi ¹, Mohammad Mousavi ², Mohammad Jazayeri ³ and Asghar Ebadifar ^{2,4*}

1. Dentist, Private Practice, Tehran, Iran

2. Dentofacial Deformities Research Center, Research Institute of Dental Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3. Department of Virology, School of Public Health Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran

4. Department of Orthodontics, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Background: Vaccines are the most effective way to prevent Coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2). This study examines and compares the efficiency of AstraZeneca, Sinopharm, and Sputnik vaccines and the correlation of antibody response with age, sex, and history of corona disease in employees of Shahid Beheshti University of Medical Sciences.

Methods: 202 participants were included, of which 82 were administered the AstraZeneca, 59 were given the Sinopharm, and 61 were given the Sputnik vaccine. SARS-CoV-2 IgM and IgG antibody levels were checked four weeks after passing the second dose of all three vaccines using the enzyme-linked immunosorbent assay (ELISA) technique.

Results: There was no significant difference between the amount of IgM and IgG antibodies among three vaccines ($p=0.056$). For all three vaccines, gender and age did not significantly affect the amount of IgM and IgG antibodies. The history of infection with COVID-19 increased the antibody response ($p>0.5$).

Conclusion: The titer of IgM and IgG antibodies were not statistically significantly different. The IgM and IgG antibodies produced by vector-based vaccines are higher than the Sinopharm vaccine. Gender did not affect the produced antibody titer. No significant linear relationship was found between age and antibody titer. In people from this study who received two doses of the AstraZeneca vaccine and had a corona history, the average amount of both IgM and IgG antibodies was measured more than the other participants.

Keywords: Antibodies, COVID19 vaccines, SARS-CoV-2

To cite this article: Alavi M, Mousavi M, Jazayeri M, Ebadifar A. Evaluation of Seroconversion Rate Following SARS COV 2 Vaccination in Health Care Workers at Shahid Beheshti University of Medical Sciences. Avicenna J Med Biotech 2023;15(4):258-263.

* Corresponding author:
Asghar Ebadifar, DDS.,
Department of Orthodontics,
School of Dentistry, Shahid
Beheshti University of Medical
Sciences, Tehran, Iran
Tel: +98 21 26708362
Fax: +98 21 22403194
E-mail:
a.ebadifar@sbmu.ac.ir
Received: 8 Jan 2023
Accepted: 5 May 2023

Introduction

Three novel coronaviruses, Coronavirus Associated Severe Acute Respiratory Syndrome (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is a human-to-human transmitted and global pandemic disease ¹. SARS-CoV-2 is an enveloped single-stranded positive-sense RNA virus that caused the pandemic of coronavirus disease 2019 (COVID-19) and resulted in millions of deaths across the globe ². The genome of SARS-CoV-2 is almost 30 kb which encodes major structural pro-

teins, including spike (S) protein and accessory proteins (ORF 3a, 6, 7a, 7b, 8, and 10) ³. The S protein is essential for the life cycle of SARS-COV-2 and is considered a major target antigen for vaccines against the virus. In the host cells, the spike protein is cleaved into S1 [Receptor-Binding Domain (RBD)-containing] and S2 (non-RBD-containing) subunits ⁴.

In most communities, Healthcare workers (HCWs) are exposed to the virus at a greater level than any other society members and may be considered at an elevated risk of infection. Their role in the chain of trans-

mission is essential, through which they help control and prevent the spread of COVID-19 disease ⁵. Various forms of vaccine candidates targeting SARS-CoV-2 are classified as inactivated virus vaccines (Sinovac Biotech, Beijing, China; Sinopharm Beijing Institute of Biotechnology, Beijing, China; Bharat Biotech, Hyderabad, India), Ad26- based vector vaccine (Janssen/Johnson & Johnson, Titusville, NJ, USA), the chimpanzee adenovirus vector vaccine (AstraZeneca, Cambridge, UK/Oxford University, Oxford, UK), Ad5 and Ad26-based vector vaccine (Gamaleya, Moscow, Russia), protein subunit based vaccines (Novavax), and mRNA vaccines (Moderna, Cambridge, US/NIAID, MA, USA; Pfizer, New York, NY, USA/BioNTech, Mainz, Germany) ^{6,7}.

COVID-19 vaccinations induce adaptive protective immunity, including specific T cell and B cell antibody responses ⁸. Specific antibodies such as IgM, IgG, and IgA mainly bind to the spike protein and can neutralize the fusion and entry of SARS-CoV-2 to the host cell. Therefore, these antibodies form the 'immunological memory' and could aid in preventing the potential COVID-19 virus. The serum concentrations of these antibodies can be analyzed to assess the efficiency of different types of vaccines ⁹, in this research. We aimed to examine and compare the efficiency of Sputnik, AstraZeneca, and Sinopharm in terms of the amount of antibody produced and the correlation of antibody response with age, sex, and history of corona disease in professors, students, and staff of Shahid Beheshti School of Dentistry and employees of Shahid Beheshti University of Medical Sciences.

Due to the fact that the response of the immune system in different races and human populations is diverse, therefore, conducting this study in an acceptable population in Tehran emphasizes the importance of the work and its novelty.

Materials and Methods

The Sinopharm vaccine was given to 59 adults in two doses (BBIBP-CorV) (34 females and 25 males, mean age of 38.91 years) and 82 individuals who had been vaccinated with the two doses of the AstraZeneca (ChAdOx1 nCoV-19) (62 females and 20 males, mean age of 42.86 years) and 61 individuals who had been vaccinated with the two doses of the Sputnik (Gam-COVID-Vac) (39 females and 22 males, mean age of 39.77 years) were enrolled in this study. From each volunteer, 5 ml of fresh blood was sampled to prepare serum or plasma. Patients' information was recorded and consent was obtained from the participants for sampling and all procedures. This study was approved by the Ethics Committee of the Faculty of Dentistry of Shahid Beheshti University of Medical Sciences with the ethics code IR.SBMU.DCR.REC.1400.178.

Inclusion and exclusion criteria

We included individuals who had received two doses of the Sinopharm vaccine (BBIBPCorV), Sputnik

(Gam-COVID-Vac), or the AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccines. A history of COVID-19 infection that was confirmed, as well as present COVID-19 infection, were both exclusion criteria, in addition to a history of infections with hepatitis viruses and HIV, people with autoimmune disorders and malignancies, those with a history of allergies or anaphylaxis, those immunocompromised, those taking corticosteroids, and the ones taking immunosuppressing drugs.

Laboratory testing

After collecting venous blood samples from the people, SARS-CoV-2 neutralizing antibody (SARS-CoV-2 IgM antibody) and SARS-CoV-2 anti-RBD IgG levels (SARS-CoV-2 IgG antibody) (Pishtaz Teb Diagnostic, Tehran, Iran) were evaluated in serum using the Enzyme-Linked Immunosorbent Assay (ELISA) technique according to the company's specifications. Indirect and competitive ELISA measured SARS-CoV-2 anti-RBD IgG and SARS-CoV-2 blocking antibody levels, and the results were expressed in relative units *RU/ml* and *μg/ml*, respectively.

Statistical analysis

Descriptive statistical methods such as tables, graphs, and statistical indices were used to describe the results. Analyses were done using SPSS 26 software. The Shapiro-Wilk test was used to check the normality of data distribution. Due to the non-normal distribution of the data, ANCOVA and Kruskal-Wallis trials were used to compare the amount of IgM and IgG antibodies and the efficacy of vaccines. The Mann-Whitney test was used to compare the effect of gender in each vaccine and the impact of a history of corona disease on the increase or decrease of IgM and IgG antibodies. Regression and Scatter analysis were used to check a specific and significant relationship, including a linear relationship between age and antibody response. Statistics were considered essential for the p-values under 0.05.

Results

The comparison of SARS-COV-2 anti-RBD IgG antibody and neutralizing antibody level

The comparison of SARS-COV-2 anti RBD IgG after the first and the second dose of vaccines showed that the median serum levels of anti-RBD IgG and neutralizing antibody were higher in Astra Zeneca (AstraZeneca > Sputnik > Sinopharm) but the differences were not significant (IgM-p=0.214, respectively, Table 1) (IgG-p=0.056, respectively, Table 2). The units of values in the tables are *μg/ml*.

Correlation of the antibody titer with SEX

In all three vaccinated groups, the levels of SARS-CoV-2 neutralizing antibody and anti-RBD IgG antibody were not associated with the gender of the participants, and no significant correlation was observed (for IgM, Sputnik p=0.430-AstraZeneca p=0.816-Sino-

Seroconversion Rate Following SARS COV 2 Vaccination in Health Care Workers

Table 1. Information about IgM antibody response

Vaccine	No.	Min	Max	Average	Middle	Variance
Sputnik	61	1.28	40.00	24.16	9.2	25.00
AstraZeneca	82	1.00	40.00	26.31	36.05	18.50
Sinopharm	59	1.00	40.00	22.14	16.10	18.47

The units of values in the tables are $\mu\text{g/ml}$.

Table 2. Information about IgG antibody response

Vaccine	No.	Min	Max	Average	Middle	Variance
Sputnik	61	2.20	100.00	76.20	91.00	37.00
AstraZeneca	82	3.90	100.00	87.07	84.30	30.52
Sinopharm	59	1.30	100.00	72.12	92.80	40.66

The units of values in the tables are $\mu\text{g/ml}$.

pharm $p=0.297$ respectively, Figure 1) (for IgG, Sputnik $p=0.110$ -Astrazeneca $p=0.548$ -Sinopharm $p=0.454$ respectively, Figure 2).

Correlation of the antibody titer with age

In all three vaccinated groups, the SARS-CoV-2 neutralizing antibody and Anti-RBD IgG antibody levels were not associated with the age of the participants, and no linear correlation was observed (for IgM, Sputnik $p=0.853$ -AstraZeneca $p=0.734$ -Sinopharm $p=0.633$ respectively, Figure 3) (for IgG, Sputnik $p=0.535$ -Astrazeneca $p=0.563$ -Sinopharm $p=0.834$ respectively, Figure 4).

Correlation of the antibody titer with prior infection

The history of infection with COVID-19 within six months before the measurement of antibodies increased the antibody response. This increase in response was significant for the AstraZeneca vaccine, but not significant for the other two vaccines (for IgM, Sputnik $p=0.940$ -AstraZeneca $p=0.017$ -Sinopharm $p=0.376$ respectively, Figure 5) (for IgG, Sputnik $p=0.552$ -Astrazeneca $p=0.0001$ -Sinopharm $p=0.281$ respectively, Figure 6).




Figure 1. Average amount of IgM antibody for all three vaccines according to gender.




Figure 2. Average amount of IgG antibody for all three vaccines according to gender.




Figure 3. Scatter diagram of the relationship between IgM antibody titer and age.

Discussion

COVID-19 is still an ongoing global pandemic, and the world needs to be immunized against the virus with




Figure 4. Scatter diagram of the relationship between IgG antibody titer and age.




Figure 5. The average amount of IgM antibody for all three vaccines according to the history or lack of the previous infection with corona disease.

a vaccine to bring this pandemic to an end¹⁰. Following SARS-COV-2 infection, adaptive immunity generates the receptor binding domain neutralizing antibodies of the spike protein and nucleocapsid protein. In addition, most COVID-19 vaccines trigger neutralizing antibodies specific to the spike protein¹¹. Vaccination is considered a crucial strategy to control viral infections¹². Corona vaccines use structures similar to the spike protein of the virus. They prepare the immune system to identify the virus^{13,14}. In glycoprotein S, there is a place called the Receptor Binding Domain (RBD) through which the virus binds to its receptor on the host cell's surface¹³⁻¹⁵. Changes in this region are primarily responsible for binding to the Angiotensin-converting enzyme 2 (ACE2) receptor¹⁵.

To measure the level of immunity obtained from corona vaccine, the amount of specific IgG antibodies in




Figure 6. The average amount of IgG antibody for all three vaccines according to the history or lack of the previous infection with corona disease.

the blood is checked¹⁶⁻¹⁸. Neutralizing antibodies cause changes in the spike protein structure and the IgG antibody specifically targets the S1 subunit of the S protein and the RBD. According to the findings of this study, the amount of IgM and IgG antibodies produced as a result of vaccination was the highest in AstraZeneca, but there was no significant difference and the type of vaccine had no significant effect on the amount of antibodies. The amount of IgM and IgG antibodies produced by vector-based vaccines, AstraZeneca and Sputnik, is higher than the Sinopharm vaccine, produced using inactivated virus technology. A study showed that the amount of specific anti-spike IgG produced after the injection of AstraZeneca and Sputnik V vaccines was almost the same¹⁹. Another study showed that the performance of the Sinopharm vaccine in creating anti-spike IgG is weaker than AstraZeneca and Sputnik vaccines²⁰. According to the results of another study compared to AstraZeneca and Pfizer vaccines, Sinopharm and Sputnik V vaccines produced lower amounts of antibodies and had lower anti-RBD-ACE2 activity^{21,22}.

According to the results of this study, the amount of IgM and IgG antibodies produced as a result of vaccine injection was equal in both sexes, and no statistically significant difference was observed. A study showed no meaningful relationship between gender and IgG titer after vaccination in any Sinopharm and AstraZeneca vaccines²¹. Another study showed no statistically significant difference in IgG antibody titer in men and women who received AstraZeneca and Sinopharm vaccines²³.

This study observed no clear and significant pattern between age and the amount of IgM and IgG antibodies produced, including a linear relationship. A negative correlation between age and neutralizing IgM antibodies was shown in a study regarding Sinopharm and AstraZeneca vaccines²³. Another study showed that the amount of anti-COVID IgG antibody produced was

similar in adults aged 19 to 24 who received the AstraZeneca vaccine, but the titer of SARS-CoV-2 anti-spike IgG was lower in people over 60 receiving this vaccine^{24,25}.

Individuals with a history of corona disease are expected to have a more robust antibody response after vaccination²⁶. This study has shown that the history of infection with COVID-19 within six months before the measurement of antibodies increased the antibody response. This increase in response was significant for the AstraZeneca vaccine, but not significant for the other two vaccines. For all three vaccines, the average amount of IgM and IgG antibodies was higher in people with a history of corona disease than those who did not have an account of this disease. This difference in the amount was more remarkable for people from this study who received two doses of the AstraZeneca vaccine than those who received two doses of the Sinopharm and Sputnik vaccines. A study showed that the history of corona disease significantly affected neutralizing antibody titer and IgG antibody titer in both types of AstraZeneca and Sinopharm vaccines²⁷.

Conclusion

Our findings point to greater quantitative efficiency of the vector-based AstraZeneca and Sputnik COVID-19 vaccine over the classic inactivated Sinopharm. Our study suggests that booster vaccination is needed for subjects who have had the Sinopharm (BBIBP-CorV) vaccine and people who have had a history of corona disease before. It is better to inject the AstraZeneca vaccine.

Acknowledgement

We thank the participants for their patience and sincere help. We also thank the field workers who worked hard to collect data and specimens from the participants.

References

- Vyas AK, Varma V, Garg G, Gupta P, Trehanpati N. The role and delicate balance of host immunity in coronavirus disease-19. *Iran J Immunol* 2021 Mar;18(1):1-12.
- Nagy A, Alhatlani B. An overview of current COVID-19 vaccine platforms. *Comput Struct Biotechnol J* 2021;19: 2508-2517.
- Yu S, Chen K, Fang L, Mao H, Lou X, Li C, Zhang Y. Comparison and analysis of neutralizing antibody levels in serum after inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV vaccines in humans. *Vaccines (Basel)* 2021 Jun 2;9(6):588.
- Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC. Coronavirus vaccine development: from SARS and MERS to COVID-19. *J Biomed Sci* 2020 Dec 20;27(1): 104.
- Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. *J Clin Invest* 2015 Sep;125(9):3401-12.
- Batty CJ, Heise MT, Bachelder EM, Ainslie KM. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus two infections. *Adv Drug Deliv Rev* 2021 Feb;169:168-89.
- Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev RA. Advances in gene-based vaccine platforms to address the COVID-19 pandemic. *Adv Drug Deliv Rev* 2021 Mar;170:113-41.
- Wang J, Peng Y, Xu H, Cui Z, Williams RO, 3rd. The COVID-19 vaccine race: challenges and opportunities in vaccine formulation. *AAPS PharmSciTech* 2020 Aug 5; 21(6):225.
- Forni G, Mantovani A, COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead. *Cell Death Differ* 2021 Feb;28(2):626-39.
- St John AL, Rathore APS. Early insights into immune responses during COVID-19. *J Immunol* 2020 Aug 1;205 (3):555-64.
- Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021 Jul;27(7):1205-11.
- Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020 Feb 15;395 (10223):514-523.
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* 2020 Dec 31;383(27):2603-15.
- Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature* 2020 Oct;586 (7830):589-93.
- Logunov DY, Dolzhevikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of a rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. *Lancet* 2021 Feb 20;397(10275):671-81.
- Sagdiev R, Ivanova P, Nikolskaya P, Swift R, Smout A (17 November 2020). Mason J, Macfie N. "Russia focuses on freeze-dried vaccine doses as transport fix". Reuters. Moscow. Retrieved 20 November 2020.
- Walsh, Nick; Shelley, Jo; Duwe, Eduardo; Bonnett, William (27 July 2020). "The world's hopes for a coronavirus vaccine may run in these health care workers' veins". CNN. São Paulo. Archived from the original on 3 August 2020. Retrieved 3 August 2020.
- Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet* 2021;397(10269):99-111.

19. Goh GK, Dunker AK, Foster JA, Uversky VN. HIV vaccine mystery and viral shell disorder. *Biomolecules* 2019 May; 9(5):178.
20. Adjobimey T, Meyer J, Sollberg L, Bawolt M, Berens C, Kovacevic' P, et al. Comparison of IgA, IgG, and neutralizing antibody responses following immunization with Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 vaccines. *Front Immunol* 2022 Jun 21;13:917905.
21. Anvari E, Talepoor AG, Eshkevar Vakili M, Karami N, Ataollahi MR, Najafi G, et al. Comparison of antibody responses following vaccination with AstraZeneca and Sinopharm. *Iran J Immunol* 2022;19(3):321-9.
22. Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, et al. A comparison of four serological assays for detecting anti-SARSCoV-2 antibodies in human serum samples from different populations. *Sci Transl Med* 2020 Sep 2;12(559):eabc3103.
23. Sarker P, Akhtar E, Kuddusi RU, Alam MM, Haq MA, Hosen MB, et al. Comparison of the immune responses to COVID-19 vaccines in Bangladeshi population. *Vaccines (Basel)* 2022 Sep 8;10(9):1498.
24. Yang HS, Costa V, Racine-Brzostek SE, Acker KP, Yee J, Chen Z, et al. Association of age with SARS-CoV-2 antibody response. *JAMA Netw Open* 2021;4(3):e214302.
25. Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. *Nat Microbiol* 2021 Sep;6(9):1140-9.
26. Nagy A, Alhatlani B. An overview of current COVID-19 vaccine platforms. *Comput Struct Biotechnol J* 2021;19:2508-17.
27. Souan L, Sughayer MA, Abualhour MM, Siag M, Al-Badr S, Al-Atrash T. Comparison of the immunogenicity and protective efficacy of various SARS-CoV-2 vaccines among healthcare workers: are our white coat armies protected?. *Vaccines* 2022 Apr 20;10(5):642.